All In Biotech

Drug Trial Radar · NCT07335211

Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

206

Planned (sponsor's estimate)

Start

Jan 2026

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Huons Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension

Conditions

  • Primary Open Angle Glaucoma (POAG)
  • Ocular Hypertension

Interventions

  • HUC3-637Drug

    Ophthalmic solution instilled directly into the eye (topical ocular administration)

  • HUC3-637-RDrug

    Ophthalmic solution instilled directly into the eye (topical ocular administration)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in diurnal IOPTime frame: 12 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kangbuk Samsung Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.